Nuvation Bio Inc.
NUVB evidence brief
What we can confirm
- BioSniper Score:
- 4.4 / 10
- Market Cap:
- $2.32B
- Lead Asset:
- NUV-1511 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for NUVB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NUVB
Nuvation Bio Inc. is a global oncology company developing targeted therapies for cancer, with an approved ROS1 inhibitor (taletrectinib/IBTROZI) and a pipeline including a Phase 3 IDH1 inhibitor (safusidenib) and early-stage programs.
Key risk: High net loss
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 13 clinical trials · 3 catalysts for Nuvation Bio Inc..
Nuvation Bio Inc. is a global oncology company developing targeted therapies for cancer, with an approved ROS1 inhibitor (taletrectinib/IBTROZI) and a pipeline including a Phase 3 IDH1 inhibitor (safusidenib) and early-stage programs.
- Approved product IBTROZI (taletrectinib) for ROS1-positive NSCLC; FDA accepted sNDA with target action date January 4, 2027 [news · 2026-05-06]
- Cash & equivalents $258.6M as of 2026-06-30; net income -$62.8M for the same period [sec]
- Phase 3 SIGMA study evaluating safusidenib in IDH1-mutant astrocytoma; protocol amendment announced February 2026 [sec_mda · as of 2026-05-04]
- Pipeline includes Phase 1 candidates NUV-868 (BET inhibitor) and NUV-1511 (drug-drug conjugate) [pipeline]
- Exclusive license agreements with Eisai (Europe), Daiichi Sankyo (global safusidenib rights), and Innovent (China) [sec_mda · as of 2026-05-04]
What works
- Approved product IBTROZI (taletrectinib) generating revenue ($31.7M total revenue as of 2026-06-30) and supported by partnerships with Eisai, Innovent, and Nippon Kayaku [sec] [pipeline]
- Strong cash position ($258.6M as of 2026-06-30) expected to fund operations through at least 12 months, supplemented by anticipated IBTROZI sales [sec] [sec_mda · as of 2026-05-04]
- Global rights to safusidenib secured via amended Daiichi Sankyo agreement, enabling a Phase 3 program in IDH1-mutant glioma [sec_mda · as of 2026-05-04]
What to weigh
- Net loss of $62.8M as of 2026-06-30, reflecting substantial R&D spending and limited revenue from a single approved product [sec]
- Total debt of $248.5M as of 2026-06-30, nearly equal to cash reserves, indicating significant leverage [sec]
- Early-stage pipeline (Phase 1 NUV-868, NUV-1511) faces high competitive landscape with over 400 competitors each [pipeline]
- Dependence on regulatory milestones (e.g., sNDA action date January 4, 2027) and partnership royalties for future revenue [news · 2026-05-06]
From the filings
Quoted directly from source documents.
Approved product IBTROZI (taletrectinib) for ROS1-positive NSCLC
“Pipeline Candidate: ibtrozi Generic Name: TALETRECTINIB ADIPATE Indication: Adult patients with locally advanced or metastatic ROS1-positive ("ROS1+") non-small cell lung cancer ("NSCLC") Phase: Approved”
Pipeline
Safusidenib Phase 3 SIGMA study for IDH1-mutant astrocytoma
“Safusidenib is being evaluated against placebo in the SIGMA study, which is a randomized Phase 3 study for the maintenance treatment of patients with IDH1-mutant astrocytoma with high-risk features.”
SEC MD&A · May 4, 2026
Catalyst timeline
- 2027-03-01 · Phase2_Start — Phase 2 study of safusidenib in IDH1-mutant glioma patients who discontinued vorasidenib due to progressive disease.
- 2027-03-01 · Phase3_Start — Phase 3 randomized, double-blind, placebo-controlled study of safusidenib in Grade 2 IDH1-mutant glioma.
- 2033-06-03 · Patent_Expiry · TALETRECTINIB ADIPATE — Patent expiry for NDA219713 (taletrectinib adipate).
Risks & what to watch (4)›
Key risks
- High net loss — Net loss of $62.8M as of 2026-06-30, reflecting ongoing R&D costs and limited revenue [sec]
- Significant debt load — Total debt of $248.5M as of 2026-06-30, nearly matching cash reserves [sec]
- Regulatory dependency — Future revenue depends on sNDA approval by January 4, 2027 and other milestones [news · 2026-05-06]
- Early pipeline competition — Phase 1 candidates face over 400 competitors each, with uncertain differentiation [pipeline]
What to watch
- FDA action on IBTROZI sNDA by January 4, 2027 [news · 2026-05-06]
- Phase 3 SIGMA study (safusidenib) data and enrollment progress [sec_mda · as of 2026-05-04]
- Phase 1 results for NUV-868 and NUV-1511 [pipeline]
- Cash runway and debt management given $62.8M net loss [sec]
Sources: Catalysts · News · Pipeline · SEC MD&A · Generated October 3, 2026 · How we verify sources →
Run Nuvation Bio Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Nuvation Bio Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 1.93
Lead: Phase 1
2 candidates
3 upcoming, next in ~138d
1 buy · 6 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
230
Total value held
$908.4M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 51,989,593 | $223.0M |
| decheng capital llc | 25,954,439 | $111.3M |
| blackrock, inc. | 25,100,374 | $107.7M |
| vanguard capital management llc | 11,626,198 | $49.9M |
| omega fund management, llc | 8,081,089 | $34.7M |
| laurion capital management lp | 7,822,638 | $33.6M |
| state street corp | 6,784,927 | $29.1M |
| geode capital management, llc | 5,863,654 | $25.2M |
| bank of america corp /de/ | 3,219,826 | $13.8M |
| redmile group, llc | 3,153,256 | $13.5M |
Showing top 10 of 230 institutional holders of Nuvation Bio Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 24.1%
- Days to cover
- 15.1
- Shares short
- 50,622,584
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NUVB short interestGovernance
Frequently asked questions
What is the AI investment thesis for Nuvation Bio Inc.?
Nuvation Bio Inc. is a global oncology company developing targeted therapies for cancer, with an approved ROS1 inhibitor (taletrectinib/IBTROZI) and a pipeline including a Phase 3 IDH1 inhibitor (safusidenib) and early-stage programs.
What is Nuvation Bio Inc.'s lead drug candidate?
Nuvation Bio Inc.'s most advanced tracked candidate is NUV-1511 (Phase 1) for Advanced Solid Tumor.
What is Nuvation Bio Inc.'s next catalyst?
Nuvation Bio Inc.'s next tracked catalyst is a Phase2_Start event — "Phase2_Start: A Phase 2, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease" — expected March 1, 2027.
Who is the CEO of Nuvation Bio Inc.?
Dr. David T. Hung M.D. is the chief executive officer of Nuvation Bio Inc. (NUVB).
Where is Nuvation Bio Inc. headquartered?
Nuvation Bio Inc. (NUVB) is headquartered in New York, NY, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.